Searl gets DRAP approval for biosimilar drug

MG News | December 14, 2023 at 12:06 PM GMT+05:00

Add Mettisglobal as a Trusted Source on Google

0:00

December 14, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for ADALIMUMAB, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China, the company's latest filing on the PSX showed today.

This marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan, the notice reads.

The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan, it said.

The company said that this development aligns with its commitment to diversifying its product portfolio, thereby enhancing the quality of earnings and shareholders' value.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	170,506.31 634.15M	-0.36% -609.51
ALLSHR	102,597.99 1,100.83M	-0.03% -32.82
KSE30	51,021.03 79.10M	-0.89% -457.52
KMI30	244,736.28 154.00M	-0.41% -995.51
KMIALLSHR	66,770.85 754.12M	0.18% 120.54
BKTi	46,874.09 27.88M	-0.86% -405.50
OGTi	35,621.25 6.98M	-0.23% -83.69

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	81,275.00	82,725.00 80,640.00	890.00 1.11%
BRENT CRUDE	103.13	105.99 102.81	1.84 1.82%
RICHARDS BAY COAL MONTHLY	110.00	0.00 0.00	-5.00 -4.35%
ROTTERDAM COAL MONTHLY	110.00	110.00 108.15	2.90 2.71%
USD RBD PALM OLEIN	1,191.50	1,191.50 1,191.50	0.00 0.00%
CRUDE OIL - WTI	96.67	100.37 96.13	1.25 1.31%
SUGAR #11 WORLD	14.92	14.92 14.60	0.23 1.57%